Five-year administration of tocilizumab to a patient with rheumatoid arthritis complicated by severe chronic heart failure

Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology
Akitake SuzukiTakahiro Okai

Abstract

We herein described the long-term administration of tocilizumab (TCZ) to a patient with rheumatoid arthritis (RA) complicated by three vessel coronary artery disease and severe heart failure (HF). A 41-year-old male was admitted to our hospital with exacerbated RA and congestive HF. Cardiac ultrasonography revealed diffuse hypokinesis with a left ventricular ejection fraction (LVEF) of 16.8% and New York Heart Association (NYHA) class III/IV HF. Swelling and tenderness were noted in most of his joints. Methotrexate (MTX) was initiated during his hospitalization and TCZ was introduced 6 months later. Our patient has been treated with MTX and TCZ for five years without any adverse events, and RA and HF have remained stable. Although it may be anecdotal, we suggest that TCZ may be used as a treatment option in patients with RA complicated by severe HF.

References

Mar 17, 2012·Lancet·UNKNOWN IL6R Genetics Consortium Emerging Risk Factors CollaborationJohn Danesh
Mar 17, 2012·Lancet·UNKNOWN Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) ConsortiumJuan Pablo Casas
Jun 16, 2012·Cardiology·Lars GullestadPål Aukrust

❮ Previous
Next ❯

Citations

Jun 28, 2016·Clinical Reviews in Allergy & Immunology·Ivica Lazúrová, Ľubomír Tomáš

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

© 2022 Meta ULC. All rights reserved